Radiotherapy Market by Product (Radiotherapy Devices, Software, Service), Procedure (EBRT, Brachytherapy, Systemic Radiotherapy), Technology (IMRT, SRT, VMAT, HDRBT, LDRBT, PDRBT), Application (Prostate, Breast)-Global Forecast to 2025
The global radiotherapy market is expected to grow at a CAGR of 5.6% from 2019 to reach $10.15 billion by 2025. The factors such as growing awareness about the benefits of radiotherapy for cancer treatment, increasing incidence & prevalence of cancer, and technological advancements in the field of radiotherapy- are driving the growth of global radiotherapy market. Moreover, opportunities from developing economies and growing government investments for treatment of cancer further support the growth of this market. However, high cost and complexities associated with the radiotherapy procedures, paucity of skilled healthcare professionals, and lack of advanced infrastructure facilities hinders the growth of this market.
The overall radiotherapy market is segmented by product (radiotherapy devices, radiotherapy consumables & accessories, software, and services), procedure (external beam radiotherapy and internal beam radiotherapy), technology (external beam radiotherapy (IMRT, IGRT, SRT, 3DCRT, particle therapy, and VMAT), internal beam radiotherapy (high-dose rate brachytherapy, low-rate brachytherapy, image-guided brachytherapy, pulse-dose rate brachytherapy, intravenous systemic radiotherapy and oral systemic radiotherapy)), application (prostate, brain, breast, lung, head & neck, colorectal, cervical, and others), end user (hospitals, independent radiotherapy centers, cancer research institutes), and geography.
Based on product type, radiotherapy devices segment is estimated to command the largest share of the overall radiotherapy market in 2019 and is expected to continue its dominance during the forecast period, mainly due to higher demand for linear accelerators and particle therapy systems with increasing adoption of radiation therapy procedures for the treatment of various types of cancers.
On the basis of end user, the radiotherapy market for hospitals segment is estimated to command the largest share of the overall radiotherapy market in 2019. This is attributed to the large volume of patient admissions in hospitals for treatment of cancer and higher affordability of hospitals for high cost medical devices.
An in-depth analysis of the geographical scenario of the radiotherapy market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. North America region is estimated to hold the largest share of the overall radiotherapy market in 2019, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa. The large share of this region is mainly attributed to the well-established healthcare system in the region, greater adoption of advanced healthcare technologies, and presence of key players.
Key players operating in the global radiotherapy market are Varian Medical Systems, Inc., Elekta AB, Accuray Incorporated, C. R. Bard, Inc., Mevion Medical Systems, Inc., Hitachi, Ltd., ViewRay, Inc., Panacea Medical Technologies Pvt. Ltd., Isoray, Inc., Optivus Proton Therapy, Inc., P-Cure, Ltd., Provison Healthcare, LLC, Ion Beam Applications S.A., and Theragenics Corporation.
Scope of the Report:
Market by Procedure
- External Beam radiotherapy
- Linear Accelerator based Teletherapy
- Cobalt-60 based teletherapy
- Proton Therapy
- Internal Beam Radiotherapy
- Brachytherapy
- Systemic Radiotherapy
Market by Product
- Radiotherapy Devices
- External beam radiotherapy systems
- Conventional Linear Accelerators (LINAC)
- Conventional Cobalt-60 Teletherapy units
- Advanced Stereotactic Radiotherapy Units (Linear Accelerator/Cobalt- 60 unit)
- Cyberknife
- Gamma knife
- Tomotherapy
- Proton Therapy Systems
- Cyclotron
- Synchrotron
- Synchrocyclotron
- Internal Beam radiotherapy systems
- Brachytherapy
- Afterloaders
- Electronic Brachytherapy products
- Radiotherapy Consumables & Accessories
- External beam radiotherapy
- Cobalt-60 Source
- Others
- Internal Beam Radiotherapy
- Brachytherapy
- Brachytherapy Applicators
- Brachytherapy seeds
- Systemic Radiotherapy
- Iobenguane
- Samarium-153
- Rhenium-186
- Others
- Software
- Services
Market by Technology
- External Beam Radiotherapy
- Intensity-Modulated Radiation Therapy (IMRT)
- Image-guided Radiation Therapy (IGRT)
- Stereotactic Radiation Therapy
- 3D Conformal Radiation Therapy
- Particle Therapy
- Volumetric Modulated Arc Therapy (VMAT)
- Internal Beam Radiotherapy
- High Dose Rate Brachytherapy (HDR)
- Low Dose Rate Brachytherapy (LDR)
- Image-guided Brachytherapy (IGBT)
- Pulse Dose Rate Brachytherapy (PDR)
- Systemic Radiation Therapy
- Intravenous radiotherapy
- Oral Radiotherapy
Market by Application
- Prostate Cancer
- Brain Tumor
- Breast Cancer
- Lung Cancer
- Head & Neck Cancer
- Colorectal Cancer
- Cervical Cancer
- Others
Market by End user
- Hospitals
- Independent Radiotherapy Centers
- Cancer Research Institutes
Market by Geography
- North America
- Europe
- Germany
- France
- U.K.
- Spain
- Italy
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- India
- Japan
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Market Ecosystem
- 1.2. Currency and Limitations
- 1.2.1. Currency
- 1.2.2. Limitations
- 1.3. Key Stakeholders
2. Research Methodology
- 2.1. Secondary Research
- 2.1. Primary Research
3. Executive Summary
4. Market Insights
- 4.1. Introduction
- 4.2. Market Dynamics
- 4.2.1. Drivers
- 4.2.1.1. Growing Awareness About the Benefits of Radiotherapy for Cancer Treatment
- 4.2.1.2. Increasing Incidence & Prevalence of Cancer
- 4.2.1.3. Technological Advancements in the Field of Radiotherapy
- 4.2.2. Restraints
- 4.2.2.1. High Cost and Complexities Associated with Radiotherapy Procedures
- 4.2.2.2. Paucity of Skilled Healthcare Professionals
- 4.2.2.3. Lack of Advanced Infrastructure Facilities
- 4.2.3. Challenges
- 4.2.3.1. Difficulties in Visualizing Tumours during Radiotherapy Procedures
- 4.2.3.2. Risks due to Radiation Exposures
- 4.2.4. Opportunities
- 4.2.4.1. Significant Opportunities from Developing Economies
- 4.2.4.2. Growing Government Investment for Treatment of Cancer
5. Radiotherapy Market, by Procedure
- 5.1. Introduction
- 5.2. External Beam Radiotherapy
- 5.2.1. Linac Based Teletherapy
- 5.2.2. Proton Therapy
- 5.2.3. Cobalt-60 Based Teletherapy
- 5.3. Internal Beam Radiotherapy
- 5.3.1. Brachytherapy
- 5.3.2. Systemic Radiotherapy
6. Radiotherapy Market, by Product
- 6.1. Introduction
- 6.2. Radiotherapy Devices
- 6.2.1. External Beam Radiotherapy Systems
- 6.2.1.1. Conventional Linear Accelerators
- 6.2.1.2. Conventional Co-60 Teletherapy Units
- 6.2.1.3. Advanced Stereotactic Radiotherapy Systems
- 6.2.1.3.1. Gamma Knife
- 6.2.1.3.2. CyberKnife
- 6.2.1.3.3. TomoTherapy
- 6.2.1.4. Proton Therapy Systems
- 6.2.1.4.1. Cyclotron
- 6.2.1.4.2. Synchrotron
- 6.2.1.4.3. Synchrocyclotron
- 6.2.2. Internal Beam Radiotherapy Systems
- 6.2.2.1. Brachytherapy Systems
- 6.2.2.1.1. Electronic Brachytherapy Products
- 6.2.2.1.2. Afterloaders
- 6.3. Radiotherapy Consumables and Accessories
- 6.3.1. Internal Beam Radiotherapy Consumables and Accessories
- 6.3.1.1. Brachytherapy Consumables & Accessories
- 6.3.1.1.1. Brachytherapy Applicators
- 6.3.1.1.2. Brachytherapy Seeds
- 6.3.1.2. Systemic Radiation Therapy
- 6.3.1.2.1. Iobenguane (I-131)
- 6.3.1.2.2. Samarium-153
- 6.3.1.2.3. Rhenium-186
- 6.3.1.2.4. Others
- 6.4. Services
- 6.5. Software
7. Radiotherapy Market, by Technology
- 7.1. Introduction
- 7.2. External Beam Radiotherapy
- 7.2.1. Intensity-Modulated Radiation Therapy (IMRT)
- 7.2.2. Image-Guided Radiation Therapy (IGRT)
- 7.2.3. Stereotactic Radiation Therapy (SRT)
- 7.2.4. 3D Conformal Radiation Therapy (3D-CRT)
- 7.2.5. Particle Therapy
- 7.3. Internal Beam Radiotherapy
- 7.3.1. Brachytherapy
- 7.3.1.1. High-Dose Rate Brachytherapy
- 7.3.1.2. Low-Dose Rate Brachytherapy
- 7.3.1.3. Image-Guided Brachytherapy
- 7.3.1.4. Pulse-Dose Rate Brachytherapy
- 7.3.2. Systemic Radiation Therapy
- 7.3.2.1. Intravenous Radiotherapy
- 7.3.2.2. Oral Radiotherapy
8. Radiotherapy Market, by Application
- 8.1. Introduction
- 8.2. Breast Cancer
- 8.3. Prostate Cancer
- 8.4. Lung Cancer
- 8.5. Brain Tumour
- 8.6. Head and Neck Cancer
- 8.7. Colorectal Cancer
- 8.8. Cervical Cancer
- 8.9. Others
9. Radiotherapy Market, by End User
- 9.1. Introduction
- 9.2. Hospitals
- 9.3. Independent Radiotherapy Centres
- 9.4. Cancer Research Institutes
10. Radiotherapy Market, by Geography
- 10.1. Introduction
- 10.2. North America
- 10.2.1. U.S.
- 10.2.2. Canada
- 10.3. Europe
- 10.3.1. Germany
- 10.3.2. France
- 10.3.3. Italy
- 10.3.4. U.K.
- 10.3.5. Spain
- 10.3.6. Rest of Europe
- 10.4. Asia-Pacific
- 10.4.1. China
- 10.4.2. Japan
- 10.4.3. India
- 10.4.4. Rest of Asia-Pacific
- 10.5. Latin America
- 10.6. Middle East & Africa
11. Competitive Landscape
- 11.1. Competitive Growth Strategies
- 11.2. Competitive Benchmarking
- 11.3. Market Share Analysis
12. Company Profiles
- 12.1. Varian Medical Systems, Inc.
- 12.1.1. Business Overview
- 12.1.2. Financial Overview
- 12.1.3. Product Portfolio
- 12.1.4. Strategic Developments
- 12.2. Elekta AB
- 12.2.1. Business Overview
- 12.2.2. Financial Overview
- 12.2.3. Product Portfolio
- 12.2.4. Strategic Developments
- 12.3. Accuray Incorporated
- 12.3.1. Business Overview
- 12.3.2. Financial Overview
- 12.3.3. Product Portfolio
- 12.3.4. Strategic Developments
- 12.4. C. R. Bard, Inc. (A Subsidiary of Becton Dickinson & Company)
- 12.4.1. Business Overview
- 12.4.2. Financial Overview
- 12.4.3. Product Portfolio
- 12.4.4. Strategic Developments
- 12.5. Mevion Medical Systems, Inc.
- 12.5.1. Business Overview
- 12.5.2. Financial Overview
- 12.5.3. Product Portfolio
- 12.5.4. Strategic Developments
- 12.6. Hitachi, Ltd.
- 12.6.1. Business Overview
- 12.6.2. Financial Overview
- 12.6.3. Product Portfolio
- 12.6.4. Strategic Developments
- 12.7. ViewRay, Inc.
- 12.7.1. Business Overview
- 12.7.2. Financial Overview
- 12.7.3. Product Portfolio
- 12.7.4. Strategic Developments
- 12.8. Panacea Medical Technologies Pvt. Ltd.
- 12.8.1. Business Overview
- 12.8.2. Financial Overview
- 12.8.3. Product Portfolio
- 12.8.4. Strategic Developments
- 12.9. IsoRay, Inc.
- 12.9.1. Business Overview
- 12.9.2. Financial Overview
- 12.9.3. Product Portfolio
- 12.9.4. Strategic Developments
- 12.10. Optivus Proton Therapy, Inc.
12.10.1.Business Overview
- 12.10.2. Financial Overview
- 12.10.3. Product Portfolio
- 12.10.4. Strategic Developments
- 12.11. P-Cure, Ltd.
- 12.11.1. Business Overview
- 12.11.2. Financial Overview
- 12.11.3. Product Portfolio
- 12.11.4. Strategic Developments
- 12.12. Provision Healthcare, LLC
- 12.12.1. Business Overview
- 12.12.2. Financial Overview
- 12.12.3. Product Portfolio
- 12.12.4. Strategic Developments
- 12.13. Sumitomo Heavy Industries, Ltd.
- 12.13.1. Business Overview
- 12.13.2. Financial Overview
- 12.13.3. Product Portfolio
- 12.13.4. Strategic Developments
- 12.14. Ion Beam Applications S.A.
- 12.14.1. Business Overview
- 12.14.2 Financial Overview
- 12.14.3. Product Portfolio
- 12.14.4. Strategic Developments
- 12.15. Theragenics Corporation
- 12.15.1. Business Overview
- 12.15.2. Financial Overview
- 12.15.3. Product Portfolio
- 12.15.4. Strategic Developments
13. Appendix
- 13.1. Questionnaire
- 13.2. Available Customization
